January 20, 2022
2 min watch
Save
VIDEO: Tarsus CEO updates march toward approval for Demodex blepharitis treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
WAIKOLOA, Hawaii — In this video from Hawaiian Eye 2022, Bobak Azamian, MD, PhD, president and CEO of Tarsus Pharmaceuticals, discussed the company’s plans to move TP-03 toward FDA approval.
“We have a number of things happening this year,” he said. “First and foremost, our pivotal trial, SATURN-2 phase 3 trial for TP-03, for the treatment of Demodex blepharitis. That will be out early this year, and that will be followed by our NDA submission for Demodex blepharitis.”
Published by:
Sources/Disclosures
Collapse
Source:
Bobak Azamien, MD, PhD
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.